Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections
ConclusionsLefamulin at the currently approved IV dosage covers mostStaphylococcus aureus isolates when targeting drug exposure associated with bacteriostasis, suggesting potential of lefamulin for the treatment of ABSSSIs. Lefamulin may not be appropriate in ABSSSI when rapid bactericidal activity is warranted.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research
More News: Bacterial Pneumonia | Chemotherapy | Infectious Diseases | Microbiology | MRSA | Pneumonia | Skin | Study | Superbugs